i
Data from Google Finance, provided as is. Values in USD
We believe a comprehensive, data and technology driven approach to care will significantly increase the odds of permanent addiction recovery.
Together with esteemed partners, and through rigorous clinical study, we are developing a unique treatment system and highly specialized tools to personalize care, from assessment to treatment and beyond.
Addiction is an unforgiving disorder that destroys countless lives and tears apart families in nearly every corner of the globe. Long-established substance use disorder treatments manage to help a low percentage of sufferers overcome or suppress their addictions but lack long term efficacy, serving as coping mechanisms rather than addressing underlying neurological and emotional causes.
DMT has been extensively studied and is thought to be well-tolerated with few adverse effects, and is the ideal molecule for advancing and sustaining new models of psychedelic-assisted therapy. DMT has a robust and well demonstrated capacity to affect neuronal activity and promote brain plasticity when administered in the optimum set and setting, providing valuable insights, a healthier reorientation to the past, and the ability to remedy the underlying neurological and emotional mechanisms of addiction.
Used therapeutically for hundreds of years in the form of ayahuasca.
Scientifically studied from at least the 1950s onward.
Present throughout the plant kingdom.
Safe in humans & endogenous to our species.
It is a short acting drug, not lasting more than a few minutes.
With a core-concentration on advancing DMT’s therapeutic potential, Entheon is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible.
Entheon’s genetic testing subsidiary, HaluGen Life Sciences, conducts diligent genetic testing to determine the risk probability of different psychedelic molecules for a given patient before the treatment takes place.
Using patient and clinical trial data, Entheon is developing a predictive biomarker response platform in partnership with Divergence Neuro Tech. Using Divergence’s proprietary neuro platform in tandem with electroencephalographic monitoring (EEG).
Entheon’s biomarker platform, powered by AI and machine learning, will better prescribe suitable psychedelic treatments, provide real-time feedback during a psychedelic event, and inform the development of a post-therapy system of patient-specific support.
